Decision Resources’ findings, based on the Pharmacor topic “Prostate Cancer,” revealed that the launches of several promising emerging therapies for prostate cancer will drive the market’s growth from $3.6 billion in 2010 to almost three times that amount over the next 10 years.
Related Articles on Hospital Oncology:
Prostate Cancer Patients May See Better Outcomes at Academic Hospitals
Kansas’ Via Christi Hospital Joins Midwest Cancer Alliance
Barnes-Jewish Hospital Installs First-of-its-Kind Proton Accelerator
Register to Attend Webinar
Presenter:
Daniel Higgins, MBA, CPB, Medusind
Next Up in Uncategorized
-
The FDA has approved Fayuvi (rebisufligene etisparvovec-hopf), the first treatment for pediatric patients with mucopolysaccharidosis type IIIA, also known as…
-
Healthcare leaders continue to grapple with an expanding list of threats to the industry’s stability, from workforce shortages and reimbursement…
-
Northwestern Medicine Bluhm Cardiovascular Institute has opened a new location in Tinley Park, Ill. The new clinic offers echocardiograms, supervised…
Join the 500,000+ healthcare executives who start their day with Becker's
Becker's Hospital Review Newsletter is sent Monday–Sunday.
